Videos

Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer

March 13th 2025, 7:00pm

Video

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.

ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’

March 13th 2025, 4:00pm

Video

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.

Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer

March 13th 2025, 1:00pm

Video

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in terms of prostate cancer therapy.

Discussing the Mission of CURE With Our Former and New Editors-In-Chief

March 12th 2025, 7:00pm

Video

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

Targeted Axillary Dissection Offers a Precise Option in Breast Cancer

March 12th 2025, 3:00pm

Video

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.

Guiding Patients Through Shared Decision-Making in Breast Cancer Care

March 11th 2025, 9:00pm

Video

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer

March 10th 2025, 4:00pm

Video

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment

March 6th 2025, 8:00pm

Video

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC

March 6th 2025, 8:00pm

Video

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC

March 6th 2025, 8:00pm

Video

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.